On November 7, 2026, the Israeli pharmaceutical company Teva Pharmaceutical Industries announced the appointment of Dmytro Sudak as the general director of its Ukrainian division. The new leader has been working at Teva for ten years and held the position of Chief Operating Officer before the appointment.
Author: Editorial Staff of NANews
Sudak will be responsible for the strategic development of the company’s business in Ukraine, strengthening its position in the pharmaceutical market, and fulfilling key corporate tasks.
Who is Dmytro Sudak
The new general director has over 20 years of experience in the pharmaceutical industry. Before joining Teva, he held executive positions at international companies Janssen Cilag and Actavis, where he worked as a financial director.
Sudak joined the Ukrainian division of Teva in 2016 as a financial director. Later, he led the development of over-the-counter drugs, and since 2023, he has been managing the company’s operational activities.
He received an MBA degree from the Kyiv School of Economics (KSE), as well as international professional qualifications FCMA and CGMA in the field of management finance and strategic management.
The appointment was commented on by Yossi Ofek, who heads the regional cluster of Teva, which includes Israel, Ukraine, South Africa, the Middle East, and Africa. According to him, Sudak’s experience, business knowledge, and ability to unite employees will help the company maintain resilience, adapt to changes, and grow.
What Teva does in Ukraine
Teva has been present in the Ukrainian market for over 27 years. According to the company, its Ukrainian portfolio includes over 260 medicinal products, and the number of employees exceeds 350 people.
According to Proxima Research, in the first half of 2026, Teva led in remote communication indicators among the ten largest pharmaceutical marketing organizations. By the end of nine months, the company also entered the top twenty organizations by monetary volume of pharmacy sales of medicines and dietary supplements.
Despite the ongoing war, Teva maintains its activities in Ukraine. Among the declared priorities are providing patients with necessary medicines, continuity of treatment, supporting employees, and cooperating with the Ukrainian healthcare system.
The parent company Teva Pharmaceutical Industries Ltd, headquartered in Israel, has a history dating back to 1901. According to the company’s published data, its international portfolio includes more than 3500 drugs, and its staff exceeds 45,000 employees in 60 countries worldwide.